NexImmune Price Performance
NexImmune stock opened at $2.48 on Monday. The firm’s 50 day simple moving average is $4.29 and its 200-day simple moving average is $6.19. The company has a market cap of $2.59 million, a P/E ratio of -0.06 and a beta of 2.16. NexImmune has a fifty-two week low of $2.30 and a fifty-two week high of $20.35.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in NEXI. Slate Path Capital LP purchased a new position in NexImmune during the first quarter valued at approximately $352,000. First Manhattan CO. LLC. grew its position in NexImmune by 496.4% during the first quarter. First Manhattan CO. LLC. now owns 149,110 shares of the company’s stock valued at $57,000 after purchasing an additional 124,110 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in NexImmune during the first quarter valued at approximately $31,000. Citigroup Inc. purchased a new position in NexImmune during the first quarter valued at approximately $304,000. Finally, Raymond James & Associates grew its position in NexImmune by 947.0% during the first quarter. Raymond James & Associates now owns 320,622 shares of the company’s stock valued at $122,000 after purchasing an additional 290,000 shares in the last quarter. 26.26% of the stock is owned by hedge funds and other institutional investors.
NexImmune Company Profile
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
- Five stocks we like better than NexImmune
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- 2 stocks that under-promised and over-delivered on their earnings
- Breakout Stocks: What They Are and How to Identify Them
- 2 overlooked stocks that crushed earnings but traded lower
- How to Invest in Music Stocks
- 3 stocks that crushed earnings estimates and still tanked
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.